Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Remember, a prescription is not required. So no need to mess with rebates. Our choice today is cinnamon sticky bun. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value of life-saving cystic fibrosis medicines, STAT notes. In draft guidance published late last week, the National Institute for Health and Care Excellence stated that a groundbreaking treatment called Trikafta and two other cystic fibrosis medications sold by the company offer notable clinical benefits, but are not cost-effective. A final recommendation will not be released until the agency has digested public comments. But if the current recommendation is finalized, anyone with the disease will not have access going forward.
French financial prosecutors are investigating Sanofi for alleged market manipulation in connection with the 2017 launch of the Dupixment medication, La Lettre reports. The preliminary probe opened in March involves alleged dissemination of misleading information related to financial communications. Sanofi said it is unaware of the investigation and its financial information is “accurate, precise and sincere.” The asthma and skin drug has since become Sanofi’s biggest seller. Sales of the antibody treatment could surpass $10 billion this year and go well beyond if the drug’s promise in treating a chronic lung disorder is confirmed.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect